Glucocorticoid excess, either endogenous with diseases of the adrenal gland, stress, or aging or when administered for immunosuppression, induces bone and muscle loss, leading to osteopenia and sarcopenia. Muscle weakness increases the propensity for falling, which, combined with the lower bone mass, increases the fracture risk. The mechanisms underlying glucocorticoid-induced bone and muscle atrophy are not completely understood. We have demonstrated that the loss of bone and muscle mass, decreased bone formation, and reduced muscle strength, hallmarks of glucocorticoid excess, are accompanied by upregulation in both tissues in vivo of the atrophy-related genes atrogin1, MuRF1, and MUSA1. These are E3 ubiquitin ligases traditionally considered muscle-specific. Glucocorticoids also upregulated atrophy genes in cultured osteoblastic/osteocytic cells, in ex vivo bone organ cultures, and in muscle organ cultures and C2C12 myoblasts/myotubes. Furthermore, glucocorticoids markedly increased the expression of components of the Notch signaling pathway in muscle in vivo, ex vivo, and in vitro. In contrast, glucocorticoids did not increase Notch signaling in bone or bone cells. Moreover, the increased expression of atrophy-related genes in muscle, but not in bone, and the decreased myotube diameter induced by glucocorticoids were prevented by inhibiting Notch signaling. Thus, glucocorticoids activate different mechanisms in bone and muscle that upregulate atrophy-related genes. However, the role of these genes in the effects of glucocorticoids in bone is unknown. Nevertheless, these findings advance our knowledge of the mechanism of action of glucocorticoids in the musculoskeletal system and provide the basis for novel therapies to prevent glucocorticoid-induced atrophy of bone and muscle. (Endocrinology 158: 664-677, 2017) A n excess of glucocorticoids is the third most common cause of bone loss, after aging and menopause, and the leading iatrogenic cause of osteoporosis (1). Immunosuppressant therapy with glucocorticoids is highly beneficial for a wide range of inflammatory conditions. However, glucocorticoid treatment has devastating effects on the musculoskeletal system, with bone fractures occurring in approximately 30% to 50% of long-term glucocorticoid-treated patients (1-5).
The debilitating effects of glucocorticoids in muscle are of rapid onset, detected as early as 7 days after initiation of their administration in humans (6, 7) . Glucocorticoids reduce sarcolemmal excitability, decrease serum levels of creatine kinase and myoglobin, decrease the crosssectional area (CSA) of type 1, 2A, and 2B myofibers, and reduce the specific force (strength) of muscle fibers. The muscle atrophy induced by glucocorticoids is accompanied by suppression of protein synthesis, with a simultaneous increase in protein catabolism, leading to a reduced myotube diameter (8, 9) . The formation of new myotubes is also impaired as glucocorticoids inhibit myogenesis by downregulating myogenin gene expression. Glucocorticoid-induced protein catabolism in skeletal muscle is associated with enhanced Forkhead box O (FoxO)-dependent transcription of members of the protein degradation machinery, including the ubiquitinproteasome system of E3 ubiquitin ligases, the lysosomal system of cathepsins, and the calcium-dependent system of calpains (8, 10) . E3 ubiquitin ligases muscle atrophy F-box (MAFbx, also known as atrogin1) and muscle RING finger 1 (MuRF1, also known as TRIM63) are known regulators of glucocorticoid-induced muscle atrophy both in vivo and in vitro, as well as in a number of other sarcopenia-inducing conditions, including denervation, immobilization, disuse, diabetes, and renal failure (11) (12) (13) . Mice lacking MuRF1 are partially protected from the muscle loss induced by glucocorticoids, and muscle-specific deletion of the glucocorticoid receptor prevents the increased atrophy gene expression and muscle loss induced by glucocorticoids (14) (15) (16) . The ubiquitin ligase MUSA1 (muscle ubiquitin ligase of the SCF complex in atrophy-1, also known as Fbxo30) has also been associated with increased protein catabolism and reductions in total protein content in muscle models of denervation injury and disuse (17) . However, the mechanisms by which glucocorticoids upregulate the expression of atrophy-related genes have not been described. In addition, it is not known whether the reduction in bone mass induced by glucocorticoids is also accompanied by stimulation of atrophy-related genes.
In the present study, we have demonstrated that an excess of glucocorticoids increases the expression in bone in vivo and in osteoblasts and osteocytes in vitro of the traditionally considered muscle-specific E3 ligases atrogin1, MuRF1, and MUSA1. In addition, we have shown that glucocorticoids increase the expression of Notch ligands, receptors, and target genes in muscle but not in bone. Furthermore, glucocorticoid-induced expression of atrophy-related genes and muscle cell atrophy were prevented by pharmacologic inhibition of the Notch pathway. These findings demonstrate that glucocorticoid-induced loss of bone and muscle mass is accompanied by increased expression of atrophy-related genes, although the upstream mechanisms are tissue-specific. Moreover, our results have identified the Notch signaling pathway as a potential therapeutic target to prevent the skeletal muscle atrophy and weakness induced by glucocorticoids. Our study provides the mechanistic basis for combining therapies that target each tissue to treat glucocorticoid-induced osteopenia and sarcopenia and offer possible molecular approaches to prevent glucocorticoid-induced atrophy of the musculoskeletal system.
Materials and Methods

Mice
Female 16-week-old C57BL/6 mice (n = 10 per group) were randomized according to the spinal bone mineral density (BMD) into four groups and implanted subcutaneously with pellets containing placebo or prednisolone (2.1 mg/kg/d; Innovative Research of America, Sarasota, FL) for 14 or 28 days. No differences were present in total body weight among the groups before or at 14 or 28 days after pellet implantation. Bone fluorochrome labeling was performed using intraperitoneal injections of 0.6% calcein and 1.0% Alizarin red at 10 and 3 days before the end of the experiment, respectively (18) . The analyses were performed in a blinded fashion.
Muscle weight and function
The muscles were weighed immediately after dissection. In vivo and ex vivo muscle function testing was performed in female 20-week-old C57BL/6 mice (n = 10 per group) that had been randomized according to spinal BMD and lean body mass into two groups: placebo-controls and prednisone-treated mice for 28 days.
In vivo muscle function was quantified using the 1305A Whole Mouse/Rat Test System (Aurora Scientific Inc., Aurora, ON, Canada) (19) . The mice were anesthetized with isoflurane, and the right leg was shaved and cleaned with alcohol. Next, the mice were placed in the supine position with the right ankle at 90 degrees of dorsiflexion and the leg positioned perpendicular to the foot pedal. Two sterile monopolar stimulated electrodes were inserted subcutaneously near the tibial nerve, with one electrode medial to the nerve and one electrode lateral in the posterior hindlimb musculature. Electrode placement and stimulation current were adjusted to achieve the maximum twitch response and then increased to ;35 mA for plantarflexion to ensure supramaximal stimulation of the muscle fibers. The maximum isometric torque (N/m) was recorded for stimulation frequencies between 25 and 300 Hz, with a pulse width of 0.2 ms and train duration of 200 ms. Data were recorded using the Dynamic Muscle Control/Data Acquisition and Dynamic Muscle Control Data Analysis programs (Aurora Scientific Inc.).
Ex vivo muscle contractility of the extensor digitorum longus (EDL) and soleus muscles was performed as described previously (20) . In brief, the muscles were dissected from the hindlimbs during immersion in Ringer's solution consisting of 136.9 mM NaCl, 2.68 mM KCl, 1.84 mM CaCl 2 dihydrate, 1.03 mM MgCl 2 hexahydrate, 5.55 mM dextrose, 11.91 mM NaHCO 3 , and 0.44 mM NaH 2 PO 4 anhydrous at pH 7.4. Stainless-steel hooks were fastened to the tendons of the muscles using 4-0 silk sutures, and the muscles were placed between a force transducer (Aurora Scientific Inc.) and an adjustable hook. The muscles were then submerged in a stimulation chamber containing 95% oxygen/5% carbon dioxide bubbled in Ringer's solution and placed between two platinum electrodes. The muscles were stimulated to contract by the electrodes, and the contraction data were recorded using the Dynamic Muscle Control/Data Acquisition and Dynamic Muscle Control Data Analysis programs (Aurora Scientific Inc.). The muscle length was then adjusted to yield the maximum force before the initiation of force-frequency or fatigue-stimulation regimens. The force-frequency stimulation regimen triggered contraction using incremental stimulation frequencies (0.5-ms pulses at 1 to 150 Hz for 350 ms at a supramaximal voltage of 1A). Between stimulations, the muscle was allowed to rest for 1 minute for frequencies ranging from 1 to 70 Hz and for 3 minutes for frequencies ranging from 100 to 150 Hz. For the forcefrequency analysis, the specific force was calculated by dividing the absolute force by the whole muscle CSA, which was calculated using the following equation: CSA (mm 2 ) = mass
, where L o mm is the optimal length, L/L o is the fiber to muscle length ratio, and 1.06 mg/mm 3 is the density of muscle (21) . The fiber-to-muscle length ratio was 0.51 and 0.72 for the EDL and soleus muscles, respectively, in accordance with previous reports (22) . The fatigue-stimulation regimen consisted of 50 or 150 repeated stimulation pulses for the EDL or soleus muscles, respectively, at 70 Hz, occurring every 0.7 second.
Study approval
The institutional animal care and use committee at Indiana University School of Medicine approved all the animal protocols, and animal care was performed in accordance with institutional guidelines.
Tissue and BMD measurements and microcomputed tomography analysis
The mice were anesthetized by inhalation of 1.7% isoflurane (Abbott Laboratories, Chicago, IL) mixed with oxygen (1.5 L/min) and were scanned using dual energy x-ray absorptiometry with a PIXImus II densitometer (GE Medical Systems, Lunar Division, Madison, WI) (18) . The BMD of the total body, excluding the head and tail, lumbar spine (L1 to L6), and femur, and the lean body mass were quantified. Body weight and dual energy x-ray absorptiometry measurements were performed in the same cohort of animals 2 to 4 days before implantation (initial) and 14 or 28 days after implantation (final). The percentage of changes in body weight, lean body mass, and BMD were calculated using the following formula: [(final 2 initial)/initial] 3 100.
For micro-computed tomography analysis, the bones were dissected, cleaned of soft tissue, and stored in 70% ethanol until used. The distal femur and proximal tibia metaphysis was scanned at 6-mm resolution (Skyscan 1172; SkyScan, Aartselaar, Belgium). The measurements were taken 60 mm away from the growth plates, as described previously (18, 23) .
Bone dynamic histomorphometry
After micro-computed tomography analysis, the tibiae were embedded in methyl methacrylate, and thick cross-sections at the mid-diaphysis were prepared using a diamond-embedded wire saw (Histosaw; Delaware Diamond Knives, Wilmington, DE) and ground to a final thickness of 30 to 35 mm for periosteal and endosteal bone formation measurements (24) . Also, 4-mmthick longitudinal sections of the proximal half of the tibia were prepared for cancellous bone measurements. Fluorochrome labels were quantified using the OsteoMeasure High Resolution Digital Video System (OsteoMetrics, Decatur, GA) (25) . To calculate the bone formation rate per bone surface (BFR/BS) when only single labels were present, a value of 0.1 mm/d was used for the mineral apposition rate (25, 26) . The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (27) .
Ex vivo bone and muscle organ cultures
The femoral and tibial long bones were harvested from C57BL/6 female and male mice, and the marrow was flushed out using a sterile syringe. The bones were then maintained in a-minimal essential medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA) for 24 hours, followed by the addition of 1 mm dexamethasone or vehicle (ethanol), in the absence or presence of 5 mM g-secretase inhibitor XX (GSI-XX), and cultured for an additional 6 hours. The tibialis anterior muscles were isolated from 1-month-old C57BL/6 female and male mice and placed in 48-well plates. The muscles were rinsed with phosphatebuffered saline and incubated in Dulbecco's modified Eagle medium (DMEM) containing 10% FBS and 1% penicillin/ streptomycin (Life Technologies) overnight. Media were replaced with DMEM plus 10% FBS containing dimethyl sulfoxide or 0.1 mm GSI-XX, together with vehicle or 1 mm dexamethasone for 12 or 24 hours. Messenger RNA (mRNA) was isolated from the bone and muscle samples to examine gene expression.
Cell culture
Murine bone marrow-derived OB-6 osteoblastic cells (28) and long bone-derived MLO-Y4 osteocytic cells (29) were cultured as previously reported. Murine C2C12 myoblasts were purchased from ATCC (Manassas, VA) and maintained at low confluence in DMEM containing high glucose, sodium pyruvate, 1% penicillin/ streptomycin (Life Technologies), and 10% FBS in 5% carbon dioxide. To induce differentiation, C2C12 cells were grown to confluency and then switched to 10% carbon dioxide and 2% horse serum DMEM (30) . After 72 hours, 1 mm dexamethasone or 0.03 mm GSI-XX, or both, were added for 24 hours, and the cells were fixed for myotube diameter measurement.
RNA extraction and quantitative polymerase chain reaction
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA), and complementary DNA (cDNA) was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Inc., Foster City, CA). Quantitative polymerase chain reaction was performed as previously described (25) . Relative mRNA expression levels were normalized to the housekeeping genes mitochondrial ribosomal protein S2 (Rplp2) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the ΔCt method (23, 25) . All primers and probes were designed using the Assay Design Center (Roche Applied Science, Indianapolis, IN) or were commercially available (Applied Biosystems, Inc., Foster City, CA).
Myotube diameter measurement
The C2C12 myotube diameter was measured, as previously reported (30) . In brief, the cells were fixed and permeabilized in ice cold acetone/methanol (1:1) at 220°C for 20 minutes and rehydrated for 10 minutes in phosphate-buffered saline at room temperature. Subsequently, the cells were incubated with an antibody against myosin heavy chain (catalog no. MF 20, Resource Identification: AB_2147781; Developmental Studies Hybridoma Bank, Iowa City, IA) overnight at 4°C with gentle agitation, followed by incubation with anti-mouse IgG labeled with green fluorescent Alexa Fluor 488 dye as secondary antibody (catalog no. A-11001, Resource Identification: AB_2534069; Life Technologies), for 1 hour at room temperature and protected from light ( Table 1 ). The nuclei were stained with 4 0 ,6-diamidino-2-phenylindole and the images captured on an Axio Observer.Z1 microscope (Carl Zeiss AG, Oberkochen, Germany). The myotube diameter was measured using ImageJ analysis software (Wayne Rasband, National Institutes of Health, Bethesda, MD). All treatment conditions were performed in triplicate.
Statistical analysis
Data are expressed as the mean 6 standard deviation. Sample differences were evaluated using SigmaPlot, version 12.0 (Systat Software, Inc., San Jose, CA). Differences between groups were detected using the Student t test or two-way analysis of variance (ANOVA) followed by the Tukey post hoc method. The force-frequency relationships of muscle contraction, both ex vivo absolute and specific force and in vivo plantarflexion torque, and fatigue curves were analyzed using a mixed-model, two-way repeated-measures ANOVA followed by Tukey post hoc tests. To determine the potential differences in fatigability, ex vivo fatigue data were also analyzed using ordinary least squares regression on the group mean data for each stimulation number. For both treatment groups (glucocorticoid and placebo), two regressions were calculated: one fit to the first 10% of the stimulations and one fit to the last 90% of the stimulations. Differences in slope between the two groups for the 10% data and 90% data were compared using the Student t test, as previously reported (31) (32) (33) .
Results
Glucocorticoids induce atrophy in bone and muscle in vivo
The total BMD and total, femoral, and spinal BMD were decreased by glucocorticoids after 14 or 28 days [ Fig. 1(A) ]. The trabecular thickness of cancellous bone of the distal femur and proximal tibia metaphysis were also reduced after 14 days [ Fig. 1(B) ]. Other bone microarchitecture indexes were not different between the placebo and glucocorticoid-treated mice (data not shown). The BFR/BS was suppressed by 14 days in the cancellous bone of the proximal tibia and in the periosteal and endocortical surfaces of the tibia mid-diaphysis [ Fig.  1(C) and 1(D) ]. The decrease in BFR/BS resulted from the decrease in the mineral apposition rate and the mineralizing surface per bone surface in all bone envelopes.
Glucocorticoids also caused muscle atrophy, as measured by reductions in total lean mass, an index of skeletal muscle mass, after 14 or 28 days [ Fig. 2(A) ]. In addition, glucocorticoids decreased at both time points the mass of the tibialis anterior [ Fig. 2 Fig. 2(D) ]. In the experiment in which the soleus mass had not decreased, glucocorticoid administration still reduced the ex vivo contractility force generated by both EDL and soleus muscles in response to the force-frequency and fatigueelectrode stimulation regimens [ Fig. 2(D) ]. The EDL and soleus muscles from mice receiving glucocorticoids both exhibited a reduction in absolute contraction force compared with the muscles from mice receiving placebo, as quantified by the force-frequency test [ Fig. 2(D) , middle panels]. However, only the soleus muscles from the glucocorticoid-treated mice exhibited a reduced specific contraction force compared with placebo. In contrast, the specific contraction forces exhibited by EDL muscles were not different between the 2 groups, indicating that the decreased absolute force displayed by the EDL muscles is driven by tissue loss. During fatigue testing, the contraction force decreased rapidly for the first 10% of stimulations and more slowly for the last 90% of stimulations, independently of muscle type or treatment. The EDL and soleus muscles from glucocorticoid-treated mice both exhibited a lower contraction force compared with the muscles from placebo-treated mice [ Fig. 2(D) , right panels]. The EDL muscles fatigued at a lower rate in the glucocorticoid-treated mice than in the placebo-treated mice in both regions of the curve, as demonstrated by the statistically significant lower slope values of the regression lines compared by t test [Fig. 2 ]. In contrast, the soleus muscles from the glucocorticoid-treated mice fatigued at the same rates as in the placebo-treated mice in both the first 10% and last 90% of the stimulations, and the slopes of the regression lines were not significantly different statistically between the 2 groups. The EDL muscles from the glucocorticoid-treated mice reached their lowest contraction force sooner than the EDL muscles in the placebo treated mice (at approximately 40 vs 50 stimulations) [ Fig. 2(D) , right panels]. In contrast, the soleus muscles from the glucocorticoid-treated and placebotreated mice reached their lowest contraction force at the same stimulation number (approximately 120 simulations). These results suggest that glucocorticoid affects the endurance of fast-vs slow-twitch muscles differently. In addition, glucocorticoids reduced the maximum plantarflexion torque assessed in vivo at 14 and 28 days of treatment [ Fig. 2(E) ]. This test reflects the combined strength of the posterior compartment leg muscles (gastrocnemius, soleus, tibialis posterior, fibularis brevis and longus, flexor hallucis longus, flexor digitorum longus, and plantaris muscles). Thus, prednisolone administration consistently induced muscle atrophy and muscle weakness in our murine model of glucocorticoid excess.
Glucocorticoids increase the expression of atrophy genes in bone and muscle in vivo and in vitro
Earlier evidence showed that muscle atrophy induced by injury or disuse is associated with increased expression Figure 1 . Glucocorticoids induce atrophy of bone and suppression of bone formation. Female C57BL/6 mice were implanted with pellets releasing 2.1 mg/kg/d of prednisolone or placebo, and BMD was assessed 14 or 28 days later. (A) Percentage of change in BMD was measured using dual energy x-ray absorptiometry and calculated from initial scans performed before pellet implantation and final scans performed at the indicated points. (B) Trabecular thickness was measured by micro-computed tomography analysis at the distal femur and proximal tibia metaphysis. Dynamic histomorphometric parameters on (C) the cancellous bone of proximal tibia and (D) periosteal and endocortical surfaces of the tibia mid-diaphysis were measured in mice treated for 14 days with placebo or prednisolone. Bars represent mean 6 standard deviation; n = 7 to 10 mice. *P , 0.05 vs placebo-treated mice by Student's t test. MAR, mineral apposition rate; MS/BS, mineralizing surface per bone surface.
of the E3 ubiquitin ligases atrogin1, MuRF1, and MUSA1, with consequent increases in protein ubiquitination, proteasomal protein catabolism, and reductions in total protein content (11, 17, 37) . Traditionally, atrogin1, MuRF1, and MUSA1 have been considered as selectively expressed in skeletal muscle.
However, detectable levels of these transcripts were also found in bone at lower detection levels, with average Ct values of approximately 30 in bone compared with cycle threshold values of 20 to 25 in the tibialis anterior and soleus muscles (when the same amount of cDNA from bone and muscle samples was used, and gene expression Muscle function testing performed in vivo 14 and 28 days after pellet implantation. Bars represent mean 6 standard deviation; n = 7 to 10 for (A and C) and n = 8 to 10 for (D and E). *P , 0.05 vs placebo by Student's t test for (A to C) and muscle weights in (D). *P , 0.05 vs placebo by two-factor, mixed-model repeated measures ANOVA, followed by Tukey post hoc method for muscle functionality tests in (D and E). For the fatigue tests in (D), regression line equations for EDL muscles were as follows: for the first 10% of stimulations, y = 20.5387x + 22.784 (placebo) and y = 20.3549x + 17.033 (glucocorticoids) (P , 0.05 by t test); for the last 90% of stimulations, y = 20.1601x + 20.474 (placebo) and y = 20.102x + 15.181 (glucocorticoids) (P , 0.05 by t test). Regression line equations for soleus muscles were as follows: for the first 10% of stimulations, y = 20.0658x + 11.72 (placebo) and y = 20.0641x + 9.2375 (glucocorticoids) (P = NS by t test); for the last 90% of the stimulations, y = 20.0102x + 10.778 (placebo) and y = 20.0097x + 8.2384 (glucocorticoids) (P = NS by t test). press.endocrine.org/journal/endowas quantified in the same quantitative polymerase chain run and analyzed with the same threshold). Glucocorticoids increased the expression of atrogin1 and MuRF1 after 14 or 28 days in both bone and the tibialis anterior muscle [ Fig. 3(A) ]. MUSA1 expression was also increased in bone and the tibialis anterior muscle from mice receiving prednisolone for 28 days. Consistent with the previously reported resistance to glucocorticoids of type I slow-twitch muscle fibers (34, 35) , 14 days of glucocorticoid exposure did not increase atrophy gene mRNA expression in the slow-twitch-dominated soleus muscle. However, after 28 days of glucocorticoid exposure, the atrogin1 and MuRF1 expression levels were increased in the soleus. Also, the increase in atrogin1 and MuRF1 expression in the tibialis anterior and soleus was greater after 28 days than after 14 days of glucocorticoid administration. Glucocorticoids also increased atrophy gene expression in ex vivo bone organ cultures [ Fig. 3 Glucocorticoids increase expression of Notch signaling pathway components in skeletal muscle but not in bone In vivo glucocorticoid administration to mice for 14 or 28 days did not alter the levels of the Notch receptors 1 to 4, the Notch ligands Dll1 and Jag1, or the Notch target genes Hey1 and Hes1 in bone, when analyzed using twoway ANOVA [ Fig. 4(A) ]. In addition, dexamethasone decreased the expression of Notch ligand Dll1 and Notch target genes Hey1 and Hes1 without altering the levels of Notch receptors 1 to 4 in both femoral and tibial ex vivo bone organ cultures [ Fig. 4(B) ]. Notch ligand Jag1 mRNA levels were also decreased by dexamethasone in femoral bone organ cultures; however, Jag1 expression was not affected in tibial organ cultures. Glucocorticoids also decreased the expression of most Notch receptors and ligands, with the exception of Notch 4 expression, which was increased in OB-6 and absent in MLO-Y4 cells [ Fig. 4  (C) and 4(D) ]. The expression of the Notch target gene Hes1 was decreased by dexamethasone in both cell types, but Hey1 was only decreased in OB-6 cells. Thus, overall, glucocorticoids did not increase, and in some cases decreased, the expression of Notch signaling components in bone in vivo, ex vivo, or in vitro.
In contrast to bone, in vivo glucocorticoids increased the levels of Notch receptors, ligands, and target genes in the tibialis anterior muscle at both 14 and 28 days (Fig.  5) . In addition, the increase in the expression of Notch receptors 1 to 3 and Hey1 and Hes1 was greater after 28 days than after 14 days of glucocorticoid administration. The addition of dexamethasone for 12 hours did not alter the expression of Notch receptors or ligands in ex vivo organ cultures of the tibialis anterior muscle; however, after 24 hours, it had increased the expression of Notch3 and 4 and Jag1 [ Fig. 6(A) and 6(B) ]. Furthermore, the expression of several Hes/Hey Notch target genes was increased by dexamethasone after both 12 and 24 hours in these ex vivo organ cultures. Moreover, addition of the Notch signaling pharmacologic inhibitor GSI-XX effectively blocked both the increase in Notch target genes and components of the pathway [ Fig. 6 (A) and 6(B)] and the increase in atrogin1, MuRF1, and MUSA1 gene expression resulting from dexamethasone [ Fig. 6(C) ]. In contrast, GSI-XX did not prevent the increase in atrogin1 and MuRF1 in bone organ cultures [ Fig. 6(D) ]. In addition, dexamethasone induced an ;20% reduction in myotube diameter of C2C12 cells, and this reduction was also prevented by the GSI-XX inhibitor [ Fig. 6(E) ]. These results suggest that the upregulation of atrophy-related genes and myotube atrophy induced by glucocorticoids is at least partially mediated by activation of the Notch signaling pathway in muscle but not in bone.
Discussion
The results of the present study have demonstrated that glucocorticoids activate different signaling pathways in bone and muscle that result in the upregulation of atrophy-related E3 ubiquitin ligases. We also identified the Notch signaling pathway as a potential target to prevent glucocorticoid-induced muscle atrophy (Fig. 7) .
Our findings demonstrate that glucocorticoids increase the expression of several E3 ubiquitin ligases in both bone and muscle in vivo in the well-established model of glucocorticoid excess, in ex vivo bone and muscle organ cultures, in in vitro osteoblastic and osteocytic cell lines, and in myoblasts and myotubes. To the best of our knowledge, this is the first report of expression in bone of atrogin1, MuRF1, and MUSA1, previously considered muscle-specific atrophy genes, and their upregulation by glucocorticoids. The relevance of atrophy gene expression for the action of glucocorticoids in bone is unknown. However, earlier studies have shown that genetic global deletion in mice of MuRF1 protects from the loss of bone induced by hindlimb unloading (38) . MuRF1 knockout mice were also protected from the decrease in histomorphometric measures of bone formation and the increase in osteoclasts in this model (38) . Glucocorticoids promote the transcription of atrophy genes in vivo, ex vivo, and in vitro. (A) mRNA levels were quantified in vertebral bone L4 (bone) and tibialis anterior (TA) and soleus muscle preparations. The transcripts were normalized to the levels of the housekeeping gene GAPDH. Bars represent the mean 6 standard deviation; n = 5 to 7 for L4; n = 8 to 10 for tibialis anterior and soleus. *P , 0.05 vs placebotreated mice; # P , 0.05 vs 14-day glucocorticoid-treated mice, by two-way ANOVA followed by Tukey post hoc method. (B) Gene expression in bones from C57BL/6 mice cultured with vehicle or 1 mm dexamethasone for 6 hours. Bars represent mean 6 standard deviation; n = 9 to 12. *P , 0.05 vs vehicle-treated cells by Student's t test. (C) OB-6 osteoblastic cells and (D) MLO-Y4 osteocytic cells were treated with vehicle or 1 mm dexamethasone for 24 hours. RNA was extracted, and atrogin1 and MuRF1 levels were quantified using quantitative polymerase chain reaction. Bars represent mean 6 standard deviation; n = 5 to 6. *P , 0.05 vs vehicle-treated cells by Student's t test. (E) C2C12 myoblasts were kept in growing media or induced to differentiate into myotubes for 6 days. Cells were treated with vehicle or 1 mm dexamethasone for 24 hours, RNA was extracted, and atrogin1 and MuRF1 levels were quantified by quantitative polymerase chain reaction. The transcripts were normalized to the levels of the housekeeping gene GAPDH. Bars represent mean 6 standard deviation; n = 3 for myoblasts; n = 6 for myotubes. *P , 0.05 vs vehicle-treated cells by Student's t test. doi: 10.1210/en.2016-1779 press.endocrine.org/journal/endo This evidence, together with our present findings, raises the possibility that upregulation of MuRF1 and, potentially, other atrophy-related genes, contributes to the reduced bone formation and increased bone resorption induced by glucocorticoids and suggests that targeting the atrophy pathway could interfere with glucocorticoid action in bone. Future studies will be required to directly examine the role of atrophy-related genes in glucocorticoid-induced bone disease. Extensive evidence has demonstrated that the C57BL/6 mouse model of glucocorticoid excess used in our study reproduces their deleterious effects on bone (39) (40) (41) . In addition, we recently reported that glucocorticoids also decrease muscle mass in this model (41), and we have now shown that glucocorticoids decrease skeletal muscle mass as early as 14 days of administration, quantified by lean body mass and the mass of individual muscles, in particular, those rich in fast-twitch fibers such as the EDL. Importantly, muscles from glucocorticoid-treated mice exhibited decreased strength (force), quantified ex vivo by contractility tests of individual muscles and in vivo by measuring the isometric plantarflexion torque generated by muscles of the posterior compartment of the leg. Remarkably, we detected decreased strength (specific force) in the slow-twitch soleus muscle in the absence of a reduction of soleus mass, suggesting that glucocorticoids might alter muscle function in the absence of detectable tissue loss, at least in muscles traditionally considered resistant to glucocorticoids (34, 35) . In contrast, the reduction in strength in the EDL muscle can be explained by the loss of muscle mass, because it is corrected by normalizing per tissue mass. The lower rate of fatigue detected in the fast-twitch EDL muscles treated with glucocorticoids compared with placebo-treated muscles can potentially be explained by the composition of EDL muscles, which mainly consist of the highly fatigable myosin-rich type 2 fibers. The latter are preferential targets of glucocorticoid-induced muscle atrophy (42, 43) . Therefore, glucocorticoid treatment might induce loss mainly of highly fatigable fibers, and thus the remaining fibers fatigue more slowly in the EDL muscles from animals treated with prednisolone. In contrast, slow-twitch soleus muscles fatigue at the same rate in glucocorticoid-and placebo-treated mice despite the reductions in overall strength induced by glucocorticoids, revealing another distinction between the effects of glucocorticoids according to the muscle type. This effect might in part explain the proximal myopathy seen in patients with diseases of excess corticosteroid secretion and patients treated with pharmacological doses of corticosteroids. The present findings with the C57BL/6 mouse model of glucocorticoid excess are consistent with the previously reported reduction in muscle fiberspecific force in humans treated with glucocorticoids (7). The reduction in muscle mass correlated with increased expression of the atrophy genes. Future studies are warranted to establish the role of E3 ubiquitin ligases in the muscle weakness induced by glucocorticoids.
Glucocorticoids decrease the C2C12 myotube diameter by 20%. This decrease is comparable with that reported in earlier studies for the effects of glucocorticoids in vivo and in vitro (7, 15, 16, 35, 44) and with starvation (35, 45) or denervation (16, 45) in similar systems. Furthermore, decreases of 10% to 17% in myotube diameter of muscle fibers translate into press.endocrine.org/journal/endo reductions of 25% to 35% in strength (specific force) with glucocorticoid administration in humans. This suggests that modest reductions in myotube diameter result in notable impairment in muscle function (7) .
Activation of the Notch signaling pathway has been shown to be required for expansion of the satellite cell population, a known critical event for skeletal muscle repair (46, 47) . In addition, Notch signaling inhibits myogenic differentiation of progenitor cells by decreasing MyoD and myogenin expression and reducing MyoD activity (46, 48, 49) . These findings support the notion that Notch signaling is crucial for maintaining the selfrenewal capacity of muscle satellite cells. The present study has revealed a role for the Notch pathway in the frame of glucocorticoid excess, because the expression of the components of this pathway was strikingly upregulated by glucocorticoids in skeletal muscle. Moreover, inhibition of Notch signaling with GSI-XX blocked the upregulation of atrophy-related genes and prevented the reduction in C2C12 myotube diameter induced by glucocorticoids.
In contrast to the effects of glucocorticoids on muscle, glucocorticoids did not increase the expression of components of the Notch pathway in our in vivo, ex vivo, or in vitro models of bone and osteoblastic/osteocytic cells. Moreover, the expression of some components of the pathway was decreased in the cultured bones and cells. Nevertheless, the Notch pathway was not altered by glucocorticoids in bone in vivo. Earlier work showed transient increases in Notch1 and Notch2 gene expression in osteoblastic MC3T3 cells treated with cortisol (50) . However, similar to our results, the expression of Dll1 and Jag1 Notch ligands was not altered by cortisol treatment in that previous study. Therefore, we can conclude that glucocorticoids activate Notch signaling in muscle, but not in bone, to induce atrophy. The mechanism underlying the upregulation of atrophy genes by glucocorticoids in bone remains unknown. However, it is possible that FoxO transcription factors are involved. In muscle, FoxO family members (FoxO1, 3, and 4) regulate the expression of atrogin1, MuRF1, and MUSA1 and are required for the full atrophic response to several inducers of skeletal muscle wasting, including starvation or fasting, denervation, and chronic kidney disease (44, 45, 51) . In bone, FoxOs are activated by, and are critical for, the defense against oxidative stress (reactive oxygen species [ROS]) (52) . In addition, at least a part of the effects of glucocorticoids in bone result from accumulation of ROS and endoplasmic reticulum stress and are abolished by ROS or endoplasmic reticulum stress inhibitors (40) . Furthermore, activation of FoxO in osteoblasts by glucocorticoids is blocked by ROS inhibition (53) . Moreover, FoxO-mediated transcription is favored over Wnt/b-catenin transcription (53) . Also, activation of Wnt/b-catenin signaling protects from glucocorticoidinduced osteoporosis (41) . Future studies are required to reveal the role of FoxOs in the upregulation of atrophyrelated genes by glucocorticoids in bone.
In conclusion, our study has identified atrophy-related E3 ubiquitin ligases as potential mediators of bone and muscle atrophy induced by an excess of glucocorticoids and points toward the Notch signaling pathway as a treatment target to prevent glucocorticoid-induced muscle atrophy. These findings provide the basis for combination therapy using inhibitors that target signaling upstream of atrophy-related genes in each tissue to prevent glucocorticoid-induced osteopenia and sarcopenia. press.endocrine.org/journal/endo
